Highest-materiality recent filing
USBC approves reverse stock split 1:2 to 1:5; tokenized deposit product testing advances
Majority holder Goldeneye 1995 LLC (92.2% voting power) approved reverse split via written consent on June 15, 2026.
USBC sells legacy sensor business for $1, retains 10% revenue share; provides $450k loan
Divested non-invasive sensor tech business for $1 plus 10% revenue share on future Covered Products.
USBC regains NYSE American listing compliance; delisting risk resolved
NYSE American notified USBC on March 27, 2026 of full compliance with continued listing standards.
USBC signs definitive triparty agreement with Uphold and Vast Bank for tokenized deposits
Agreement dated Jan 20, 2026; press release Jan 26, 2026.
USBC shareholders approve amended 2021 equity plan, adding 65M shares
Plan approved with 362.7M for vs. 2.4M against; authorized shares increased by 65M to 115M plus evergreen.
USBC completes name/ticker change to USBC after $125M acquisition by Goldeneye 1995 LLC
Name changed from Know Labs to USBC, Inc.; ticker changed to USBC on NYSE American, effective Aug 15, 2025.
Know Labs sells ~81% control for 1,000 Bitcoin & $15M; new CEO, CFO, COO assume roles
Goldeneye 1995 LLC (Robert Kidd) acquired ~81% of Know Labs common stock on a fully diluted basis for 1,000 Bitcoin + $15M cash.
Authorized common shares increased from 7.5M to 750M (approved 5,036,628 For, 329,796 Against).
Greg Kidd affiliate to acquire controlling interest in Know Labs with Bitcoin treasury strategy
Buyer to pay 1,000 Bitcoin + $12M-$15M cash for shares at $0.335/share, achieving controlling interest.
Know Labs effects 1-for-40 reverse stock split, trading moves to OTC Pink under KNWND
Reverse split at 1:40 effective Feb 19, 2025; authorized shares cut from 300M to 7.5M.
NYSE American commences delisting of Know Labs; stock moves to OTC Pink
NYSE Regulation suspended trading and initiated delisting due to bid price under $0.10.
Know Labs enters ATM agreement with JonesTrading for up to $5M common stock offering
Entered Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC as sales agent.
Know Labs extends CEO's warrants for 5.77M shares at $0.25 to 2030
Four warrants totaling 5,769,715 shares of common stock at $0.25 per share.
Know Labs gets NYSE American nod on compliance plan; extension to Mar 2026
Stockholders' deficit of $4.6M as of June 30, 2024; losses in five most recent fiscal years.
Know Labs stockholders approve increase in authorized shares to 300M and equity plan shares to 40M
Stockholders approved amendment to certificate of incorporation increasing authorized common shares from 200M to 300M.
Know Labs receives NYSE American delisting notice for stockholders' equity deficiency
As of June 30, 2024, stockholders' deficit of $4.6M; losses in five most recent fiscal years triggered Sections 1003(a)(ii) and (iii).
Know Labs raises $1.655M in registered direct offering of 6,365,385 units at $0.26/unit
Each unit consists of one share common stock and one warrant to buy one share at $0.26.
Study in Diabetes Technology & Therapeutics: RF sensor and ML algorithm classified glycemic status with 93.37% accuracy vs. venous blood glucose.
Know Labs enters $5M at-the-market offering agreement with Benchmark
ATM agreement with Benchmark Company allows sale of up to $5M of common stock at prevailing market prices.
Know Labs corrects warrant count to 6M shares in $14.4M convertible note facility with Lind
Initial $4.8M senior convertible note (0% interest) for $4M purchase price; conversion at $1.00/share.
Know Labs’ RF glucose sensor achieves 11.1% MARD in first venous-blood study
Overall MARD of 11.1±2.1% in test dataset; similar accuracy in normoglycemic (11.0%) and hyperglycemic (11.5%) ranges.
Know Labs secures up to $12M in convertible note funding from Lind Global Fund II
Initial close: $4M cash for a $4.8M face-value convertible note; conversion price $1.00/share (50% premium to $0.667 close).
Know Labs Q1 net loss $3.45M, EPS -$0.04; cash burn $3.39M; going concern remains
Net loss $3.45M vs $3.82M year ago; EPS loss -$0.04 improved from -$0.08.
Know Labs Adds Four New Members to Medical and Scientific Advisory Board
Jeff Hitchcock, founder of Children with Diabetes, appointed to board.
The Conley Amendment provides that Mr. Conley’s employment term will terminate automatically upon the consummation of the transactions contemplated by Purchase Agreement.
On September 6, 2024, Timothy Londergan, a member of the Board of Directors of Know Labs, Inc. (the “Company”), tendered his resign from the Company's Board of Directors, effective September 6, 2024.
On November 3, 2023, the Board of Directors (“Board”) of Know Labs, Inc. (the “Company”) appointed Larry K. Ellingson, John Cronin and Timothy M. Londergan, as new non-employee members of the Board.
On November 3, 2023, the Board of Directors (“Board”) of Know Labs, Inc. (the “Company”) appointed Larry K. Ellingson, John Cronin and Timothy M. Londergan, as new non-employee members of the Board.
On November 3, 2023, the Board of Directors (“Board”) of Know Labs, Inc. (the “Company”) appointed Larry K. Ellingson, John Cronin and Timothy M. Londergan, as new non-employee members of the Board.
Masanori King Takee, Chief Technology Officer, 43.
Mr. Trautwein has held the Chief Marketing Officer title since then and now transitions to Chief Commercial Officer.
Jessica English, Chief Marketing Officer, 37.
On January 23, 2023, Phillip A. Bosua resigned from the Board of Directors and from his position as Chief Executive Officer of Know Labs, Inc.
On January 23, 2023, the Board of Directors of the Company appointed Ronald P. Erickson, the current Chairman of the Board, to the position of Chief Executive Officer of the Company.
Peter Conley, Chief Financial Officer and SVP Intellectual Property (IP) – Mr. Conley brings over 34 years of corporate finance and equity capital markets experience, more than $5B in equity transactions, and over 20 years of specialization in strategic IP analysis, IP development and IP monetization to Know Labs, joining the company as Chief Financial Officer and SVP, Intellectual Property.
Steven Kent, Chief Product Officer – Mr. Kent joins Know Labs as Chief Product Officer, where he will be responsible for product development and clinical testing.
Max materiality 1.00 · Median 0.55 · Most common event other_material